{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:42:45Z","timestamp":1777480965206,"version":"3.51.4"},"reference-count":108,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Cancer chemotherapy has been shifted from conventional cytotoxic drug therapy to selective and target-specific therapy after the findings about DNA changes and proteins that are responsible for cancer. A large number of newer drugs were discovered as targeted therapy for particular types of neoplastic disease. The initial discovery includes the development of the first in the category, imatinib, a Bcr-Abl tyrosine kinase inhibitor (TKI) for the treatment of chronic myelocytic leukemia in 2001. But the joy did not last for long as the drug developed a point mutation within the ABL1 kinase domain of BCR-ABL1, which subsequently led to the discovery of many other TKIs. Resistance was observed for newer TKIs a few years after their launching, but the use of TKIs in life-threatening cancer therapy is considered as far better compared with the risks of disease because of its target specificity and hence less toxicity. In search of a better anticancer agent, the physiochemical properties of the lead molecule have been modified for its efficacy toward disease and delay in the development of resistance. Deuteration in the drug molecule is one of such modifications that alter the pharmacokinetic properties, generally its metabolism, as compared with its pharmacodynamic effects. Precision deuteration in many anticancer drugs has been carried out to search for better drugs for cancer. In this review, the majority of anticancer drugs and molecules for which deuteration was applied to get better anticancer molecules were discussed. This review will provide a complete guide about the benefits of deuteration in cancer chemotherapy.<\/jats:p>","DOI":"10.1089\/cbr.2023.0031","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:28:38Z","timestamp":1692196118000},"page":"1-18","source":"Crossref","is-referenced-by-count":0,"title":["Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery"],"prefix":"10.1177","volume":"39","author":[{"given":"Aman","family":"Mourya","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-4296","authenticated-orcid":false,"given":"Navnit","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01127.x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.10.005"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1115937"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6446(00)01540-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.112016"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq279"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.05.015"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2011.01841.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13039-020-00517-y"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2635\/5\/eurrev_201802_14310"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.4.709.709"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08980"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10025"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2009.06.001"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(81)90171-8"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.1981.tb00654.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006146"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2741"},{"issue":"12","key":"e_1_3_4_20_2","first-page":"21","article-title":"Human prostate cancer cell lines","volume":"81","author":"Russell PJ","year":"2003","unstructured":"Russell PJ, , Kingsley EA. Human prostate cancer cell lines. Methods Mol Med, 2003; 81(12):21\u201339.","journal-title":"Methods Mol Med"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915135107"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01753839"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.6.7695"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21667"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-375"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.026"},{"issue":"1","key":"e_1_3_4_27_2","first-page":"1","article-title":"Cancer: An overview cancer: An overview","volume":"8","author":"Mathur G","year":"2015","unstructured":"Mathur G, , Nain S, , Sharma P. Cancer: An overview cancer: An overview. Acad J Cancer Res, 2015; 8(1):1\u20139.","journal-title":"Acad J Cancer Res"},{"key":"e_1_3_4_28_2","first-page":"2016","article-title":"N E W S & A N A LY S I S","volume":"15","author":"Mullard A","year":"2016","unstructured":"Mullard A, , Mullard A. N E W S & A N A LY S I S. Nat Publ Gr, 2016; 15:2016.","journal-title":"Nat Publ Gr"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1470"},{"issue":"4","key":"e_1_3_4_30_2","first-page":"249","article-title":"Take free quizzes online at acsjournals","volume":"63","author":"Dy GK","year":"2013","unstructured":"Dy GK, , Adjei AA. Take free quizzes online at acsjournals. com\/ce Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin, 2013; 63(4):249\u2013279.","journal-title":"com\/ce Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.07.034"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.06.001"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00265-1"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2016.06.057"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00024669-200403040-00001"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7892601"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.69.1.373"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.084145"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2005.03.004"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.018"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2005.11.002"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.99"},{"issue":"283","key":"e_1_3_4_44_2","first-page":"101","article-title":"Tyrosine kinase\u2013role and significance in cancer","volume":"1","author":"Paul MK","year":"2012","unstructured":"Paul MK, , Mukhopadhyay AK. Tyrosine kinase\u2013role and significance in cancer. Int J Med Sci, 2012; 1(283):101\u2013115.","journal-title":"Int J Med Sci"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920009788897975"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105463"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00963"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01040-2"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01462-5"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00543-7"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353473"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgab132"},{"issue":"22","key":"e_1_3_4_53_2","first-page":"3224","article-title":"Structure-activity relationship within a series of pyrazolidinone antibacterial agents","volume":"36","author":"Ternansky RJ","year":"1993","unstructured":"Ternansky RJ, , Draheim SE, , Pike AJ, et al. Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters. J Med Chem, 1993; 36(22):3224\u20133229.","journal-title":"2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters. J Med Chem"},{"key":"e_1_3_4_54_2","first-page":"66","article-title":"The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists","volume":"154","author":"Seley-Radtke KL","year":"2018","unstructured":"Seley-Radtke KL, , Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res, 2018; 154:66\u201386.","journal-title":"Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01603-0"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2250"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1378350"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01808"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00204a010"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.10.024"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c04160"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-386009-5.00003-5"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.7b00765"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-003-0819-z"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082367"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.08.001"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1039\/C2DT31833D"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.04.003"},{"issue":"4","key":"e_1_3_4_70_2","article-title":"Deuteration as a tool for optimization of metabolic stability and toxicity of drugs","volume":"1","author":"Gupta M","year":"2017","unstructured":"Gupta M. Deuteration as a tool for optimization of metabolic stability and toxicity of drugs. Glob J Pharm Pharm Sci, 2017; 1(4):555566.","journal-title":"Glob J Pharm Pharm Sci"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo00986a023"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm4007998"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/adsc.200800407"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.5b02254"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja3041338"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol2029178"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol801763j"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.201500192"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.8b00383"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-021-00846-4"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201811522"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1002\/chem.200701147"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41929-020-0488-z"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb4129"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.1848"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138828"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00570-1"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1177\/1461444810365020"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200150502"},{"issue":"11","key":"e_1_3_4_91_2","first-page":"688","article-title":"Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: Report from a phase 1b trial","volume":"74","author":"Liu J","year":"2019","unstructured":"Liu J, , Li X, , Zhang H, et al. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: Report from a phase 1b trial. Pharmazie, 2019; 74(11):688\u2013693.","journal-title":"Pharmazie"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02005"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27504"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.01.096"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.04.071"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06391"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2013.03.038"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.04.012"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33706"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3516"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.063628"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000019"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.06.025"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201900179"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.03.088"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3299"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.8b00191"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00166"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2023.0031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2023.0031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2023.0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:15Z","timestamp":1777385475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2023.0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1089\/cbr.2023.0031"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2023.0031","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}